Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1 BIO 300 Oral Suspension
- Conditions
- Healthy Volunteer Study
- Interventions
- Drug: BIO 300 Oral Suspension
- First Posted Date
- 2024-12-18
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 56
- Registration Number
- NCT06741345
- Locations
- 🇺🇸
Nucleus Network, LLC, Saint Paul, Minnesota, United States
BIO 300 Oral Powder Safety and Pharmacokinetics
- Conditions
- Acute Radiation Syndrome
- Interventions
- Drug: BIO 300 Oral Powder
- First Posted Date
- 2020-12-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT04650555
- Locations
- 🇺🇸
Nucleus Network, Ltd (Formally Prism Research, LLC), Saint Paul, Minnesota, United States
BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients
- Conditions
- Long COVIDCOVID-19Post-acute Respiratory Complications of COVID-19Pulmonary Fibrosis
- Interventions
- Drug: BIO 300 Oral SuspensionDrug: Placebo
- First Posted Date
- 2020-07-22
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 50
- Registration Number
- NCT04482595
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸NYU Langone Health, New York, New York, United States
🇺🇸University of Texas Health Science Center at Houston, Houston, Texas, United States
BIO 300 Non-Small Cell Lung Cancer Study
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- First Posted Date
- 2015-10-05
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 21
- Registration Number
- NCT02567799
- Locations
- 🇺🇸
University of Maryland School of Medicine, Baltimore, Maryland, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Single Site, Randomized, Double-blind, Placebo Controlled Trial of NIC5-15 in Subjects With Alzheimer's Disease
- Conditions
- DementiaAlzheimer's Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- Humanetics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT01928420
- Locations
- 🇺🇸
James J Peters Veterans Affairs Medical Center, Bronx, New York, United States
- Prev
- 1
- 2
- Next
News
BIO 300 Shows Promise in Improving Pulmonary Function in Post-COVID-19 Patients
Humanetics Corporation's BIO 300 demonstrated statistically significant improvement in pulmonary function (FEV1) at 12 weeks, maintained at 12 months in post-COVID-19 patients.
Humanetics Receives Additional Funding to Advance BIO 300 for Radiation Injury Prevention
Humanetics Corporation secured an additional $5 million from the Department of Defense to further develop BIO 300, a drug aimed at mitigating harm from acute radiation exposure.